BTN1A1 is a novel immune checkpoint mutually exclusive to PD-L1.
Young-Seung KimSeung-Hoon LeeAndrew H ParkChunai WuBong-Ki HongHyunjin JungSteven Hsesheng LinStephen S YooPublished in: Journal for immunotherapy of cancer (2024)
Together, these results confirm that the potential of BTN1A1 is a bona fide immune checkpoint and a viable immunotherapeutic target for the treatment of individuals with anti-PD-1/PD-L1 refractory or resistant disease, opening new avenues to improving survival outcomes for patients with a range of cancers.